Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in North Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 532 | 20% |
| 2020 | 10 | 586 | 22% |
| 2021 | 9 | 516 | 25% |
| 2022 | 7 | 459 | 29% |
| 2023 | 9 | 422 | 34% |
| 2024 | 10 | 315 | 37% |
| 2025 from claims | – | 325 263–382 | 39% |
| 2026 forecast | – | 332 260–417 | 38% |
| 2027 forecast | – | 333 247–441 | 39% |
| 2028 forecast | – | 334 237–462 | 40% |
| 2029 forecast | – | 335 228–481 | 41% |
| 2030 forecast | – | 337 220–499 | 41% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in North Dakota; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 82% hospital outpatient, 15% office. The share outside the hospital has moved +15 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~330 | ~11 | ~280 | ~45 |
| 2027 · ~330 | ~12 | ~280 | ~43 |
| 2028 · ~330 | ~12 | ~280 | ~42 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: office about 12% (15% in 2025), hospital outpatient about 84% (82% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 84 | 6,150−1.9%/yr | −1.9%/yr | 5.5 | 21% | 5,630 in 2030−1.5%/yr |
| Illinois | 93 | 5,993−6.1%/yr | −6.1%/yr | 4.3 | 36% | 5,880 in 2030−0.3%/yr |
| Indiana | 54 | 3,762−4.3%/yr | −4.3%/yr | 5.3 | 17% | 3,750 in 20300%/yr |
| Michigan | 40 | 3,700−3.6%/yr | −3.6%/yr | 4.3 | 29% | 3,320 in 2030−1.8%/yr |
| Missouri | 44 | 2,933−12%/yr | −12%/yr | 4.7 | 20% | 2,710 in 2030−1.3%/yr |
| Wisconsin | 40 | 2,152−11%/yr | −11%/yr | 3.8 | 14% | 2,150 in 20300%/yr |
| Kansas | 37 | 2,068−4.1%/yr | −4.1%/yr | 5.1 | 37% | 1,920 in 2030−1.3%/yr |
| Iowa | 29 | 1,578−7.8%/yr | −7.8%/yr | 3.5 | 34% | 1,380 in 2030−2.2%/yr |
| Minnesota | 25 | 1,559−8.7%/yr | −8.7%/yr | 3.4 | 14% | 1,980 in 2030+4.1%/yr |
| Nebraska | 20 | 1,469−17%/yr | −17%/yr | 5.6 | 29% | 1,250 in 2030−2.7%/yr |
| South Dakota | 12 | 636+8.3%/yr | +8.3%/yr | 4.9 | 4% | 580 in 2030−1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 10 | 352−6.2%/yr | −6.2%/yr | 3.60.7× | 0% | 360 in 2030+0.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 1 | 216−1.3%/yr | −1.3%/yr | 2.30.8× | 10% | 220 in 2030+0.5%/yr |
BPH procedures in every state, and its device makers · Every procedure market in North Dakota · Every state · Compare with Ohio
Edap Technomed leads with 100% of company spending on these surgeons in 2025, +100 pts on 2024.
In 2025, 1 company reported engagement with North Dakota’s surgeons worth $137 in consulting, speaking, meals and travel tied to these products, about $14 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.